New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.
Immunotherapy for Prostate Cancer: Where Do We Go From Here?—PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies
Here we focus on alternative methods of harnessing both adaptive and innate antitumor immunity to target prostate cancer cells, and look ahead to provide a perspective on how this growing collection of immunotherapeutic approaches may ultimately be combined to target prostate cancer from a variety of angles.
This article discusses the ways in which pathologic regional nodal status affects clinical decisions about locoregional and systemic treatment, reviews published literature and guidelines, and aims to provide a practical perspective on treatment approach in the face of a broad range of data and recommendations.
This article reviews how acupuncture is thought to work, data on acupuncture for managing pain caused by cancer or by cancer treatment, how acupuncture is practiced in the US medical system, discussion of safety issues, and practical tips on how to integrate acupuncture into cancer care.
Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer
A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.
Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL.
Elimination of chemotherapy from our combination regimens should be a shared goal among researchers that will move us a step closer to more patient-friendly and scientifically driven therapies for CLL.
Until the superiority of novel agents is proven for all prognostically relevant subgroups of patients with CLL, we believe chemoimmunotherapy continues to have a role.